Uveal Melanoma (UM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Uveal Melanoma (UM) Market Outlook
Thelansis’s “Uveal Melanoma (UM)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Uveal Melanoma (UM) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Uveal
Melanoma (UM) Overview
Uveal
melanoma (UM), also known as ocular melanoma, is the most common primary
malignancy of the eye in adults, yet remains a rare disease, comprising only a
small percentage of all melanoma cases. This cancer originates from the
pigment-producing cells within the uveal tract—the iris, ciliary body, and most
frequently, the choroid—and is biologically distinct from skin melanoma,
showing poor response to standard systemic treatments like traditional
chemotherapy and immune checkpoint inhibitors. While local disease control is
often achieved through vision-preserving methods such as plaque brachytherapy
or external radiation, the most significant clinical challenge is the high rate
of metastasis, with up to 50% of patients developing advanced disease, primarily
affecting the liver in the vast majority of cases, which contributes to a poor
prognosis. This unique metastatic pattern has driven therapeutic development
toward specialized modalities, including both liver-directed regional
treatments (like chemoembolization and radioembolization) and novel systemic
immunotherapies, which, for the first time, have demonstrated an overall
survival benefit in randomized clinical trials for patients with unresectable
or metastatic disease.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment